Three Shifts Reshaping China’s Drug Payment System: Implications for Global Pharma
China’s drug payment system is shifting from isolated policy levers toward an environment defined by their interaction. Recent signals are beginning to link pricing, launch timing, and multi-payer access in ways that materially change how global pharma approaches China.
From Reference Tool to Operating Model: A Roadmap for China’s C-List
China’s C-List establishes a national reference for innovative drugs outside the NRDL—but not yet a payment system. Its impact will hinge on whether insurers and regulators can turn policy intent into a workable, risk-sustainable commercial coverage model.
China Establishes Market-Price Database, Reshaping Global Pricing Signals
China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.
China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest
China’s VBP is shifting toward biosimilars, raising strategic questions for global manufacturers: Will the country cultivate an EU-style biosimilar market—and will VBP mirror generics or follow a modified path? This series interprets early policy signals to help companies prepare.
NFRA’s Guiding Opinions: What They Mean for China’s Multi-Level Coverage Framework
NFRA’s latest Guiding Opinions signal a shift toward a more innovation-friendly commercial health insurance ecosystem. The article unpacks five key policy themes with critical implications for the C-List rollout and the building of China’s multi-level coverage framework.
Winning in China in a Multi-Level Coverage Era for Global Pharma
Success in China’s multi-level coverage era will hinge on three imperatives that upend old models and open new pathways.
▶️Making the C-List Work: Lessons and Next Steps for Pharma
The final Health Policy and Financing Panel wrapped up the C-List Masterclass with reflections, insurer perspectives, global case studies, and Q&A—highlighting how manufacturers can turn C-List inclusion into a true springboard for coverage.
▶️Frontline Perspectives: Realities and the Road Ahead for Commercial Health Insurance in China
Two senior commercial insurance leaders share candid views on China’s evolving market—what’s working, where integration lags, and if the new commercial innovative drug list could help close gaps and drive future growth.
▶️Fudan’s Wanyan Ruiyun on Huiminbao and the C-List: From Central Negotiation to Market Uptake and Insurance Innovation
Fudan expert shares insights on China’s first national negotiation for the commercial drug list—and its potential to reshape Huiminbao, influence drug pricing, accelerate insurance innovation, and transform drug distribution systems nationwide.
▶️Navigating China’s Multi-Level Coverage Framework: Insights from the C-List Strategy Panel
Industry leaders unpack China’s evolving multi-level coverage system—what the dual-list means for pricing risk, NRDL vs. commercial access, and long-term strategy in the C-List era.
